EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN..

The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

 

18-20 September 2024 Copenhagen
Close
N. Poster
Poster title
Applicant name
Status
  2-P Multiple sclerosis can be diagnosed on the basis of dissemination in space alone Wallace Brownlee Received Received
  3-P Longitudinal extensive myelitis in the elderly : MRI, biological and clinical features, etiology and prognosis in a large consecutive cohort Valentin STRUB Received Received
  8-P Efficacy of rituximab and inebilizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) : A Real-World Study. Phillippe-Antoine Bilodeau Received Received
  11-P Myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review of clinicoradiological onset features, treatment, outcomes, and geographical distribution of 4699 patients Benjamin Trewin Received Received
  14-P Meningococcal infections in eculizumab- or ravulizumab-treated patients: a clinical and real-world pharmacovigilance update across indications, including neuromyelitis optica spectrum disorder Alexia Perugini Received Received
  22-P Treatment Outcomes in a Real-World Neuromyelitis Optica Spectrum Disorder Cohort Phillippe-Antoine Bilodeau Received Received
  24-P Predictors of personality disorder scores in aquaporin-4 antibody (AQP4) positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein associated disease (MOGAD) Anna Francis Received Received
  25-P Long-term safety, effectiveness, and corticosteroid sparing effects of eculizumab in patients with AQP4-Ab neuromyelitis optica spectrum disorder: real-world data from Japan Alexia Perugini Received Received
  26-P Nationwide prevalence and incidence study of MOG-antibody associated disease in the adult population of Denmark Viktoria Papp Received Received
  29-P Prevalence and determinants of pain and its impact on the quality of life in neuromyelitis optica spectrum disorder (NMOSD): a systematic review Lilith Hauck Received Received
  33-P Correlates of sociodemographic features, healthcare access, and disability in NMOSD: Retrospective analysis of the CIRCLES cohort Sammita Satyanarayan Received Received
  36-P The impact of Nutrition on Cognitive Function in Multiple Sclerosis Patients Anna Gil Received Received
  42-P Real world data on the impact of ocrelizumab on patient-reported fatigue and quality of life in relapsing multiple sclerosis patients: Interim analysis of the observational study MoOzaRt Petra Joestingmeyer Received Received
  47-P Fatigue, Affect, and Cognitive Functioning in Multiple Sclerosis (MS) Leigh Charvet Received Received
  50-P Does Impairment in Hand Function Predict Impairment in Mobility or Information Processing in Progressive MS? Giuseppina Pilloni Received Received
  58-P Early Initiation of Ofatumumab Delays Disability Progression in People With Relapsing Multiple Sclerosis: 6-Year Results From ALITHIOS Open-Label Extension Study Sivaram Vedantam Received Received
  59-P Motor evoked potentials predict progression independent of relapse activity (PIRA) in relapsing multiple sclerosis Zido Michal Received Received
  68-P Association between alcohol consumption and disease progression in multiple sclerosis Lars Alfredsson Received Received
  70-P Introducing GLOW: An improved EDSS-derived metric for assessing Global Level of Worsening in Multiple Sclerosis Lars Forsberg Received Received
  77-P Pediatric-onset NMOSD in a cohort of 1185 patients in Latin America Milena Sales Pitombeira Received Received
  78-P Risk and onset of multiple sclerosis after infectious mononucleosis (IM): a population-based study of 650,000 cases of IM Dalia Rotstein Received Received
  91-P Driving forces: Investigating Menopauses Influence on MS Disability Progression Francesca Bridge Received Received
  92-P Reducing Postpartum MS Relapses: A Proactive Approach Celia Oreja-Guevara Received Received
  93-P Evaluation of Relapses around Pregnancy in Women with Multiple Sclerosis Stratified by Disease-Modifying Therapy Use Anna Shah Received Received
  104-P Machine Learning Model for EDSS Prediction Using Nationwide Data from the Danish MS Registry Rotem Bar-Or Received Received
  105-P Multiple sclerosis phenotypes influence MSCopilot measures: initial findings from the French real-life digital cohort Loďc Carment Received Received
  116-P Relationship between Physical Disability and Cognitive Performance with Work Productivity and Employment in Multiple Sclerosis Ronja Christensen Received Received
  163-P The binding of human myelin oligodendrocyte glycoprotein antibodies is influenced by the second transmembrane region of the myelin oligodendrocyte glycoprotein Markus Reindl Received Received
  164-P Human herpesviruses in primary progressive versus relapsing remitting multiple sclerosis patients Roberto Álvarez-Lafuente Received Received
  165-P Adolescent sleep patterns, genetic predisposition, and risk of multiple sclerosis lars alfredsson Received Received
  167-P Never too late to quit: Smoking cessation mitigates worse disease outcomes in Black persons with Multiple Sclerosis Claire Wigley Received Received
  171-P GPR17 antagonists as a novel remyelination therapy Tania Seabrook Received Received
  174-P Paramagnetic rim lesions as early markers of lesion formation and their relationship with lesion growth and brain atrophy in Multiple Sclerosis Alexander Klistorner Received Received
  178-P Choroid Plexus Volume in Temporal Relation to Relapse Activity in Multiple Sclerosis Jannis Müller Received Received
  182-P Sample size estimations for clinical trials using paramagnetic rim lesion appearance or disappearance as an endpoint Jack Reeves Received Received
  202-P Evaluating the performance of the AH-1 imaging software for the clinical management of MS patients in real world conditions SERGI VALVERDE Received Received
  210-P Magnetization transfer ratio in the cerebellum and cerebellar peduncles and its relationship to clinical outcomes for people with radiologically isolated syndrome and multiple sclerosis Lisa Eunyoung Lee Received Received
  211-P The Impact Of Ocrelizumab On Paramagnetic Rim Lesions In Multiple Sclerosis Kimberly Markowitz Received Received
  214-P Predicting longitudinal cognition using the structural and functional connectivity networks estimated with lesion masks and deep learning Ceren Tozlu Received Received
  221-P T1/T2-weighted ratio in the cervical spinal cord: a quick, clinically-feasible marker of pathology in multiple sclerosis Anna Combes Received Received
  226-P Impact of MS Imaging Analytics on MRI Report Findings Kelly Leyden Received Received
  227-P Peak-width skeletonised microstructural MRI changes and EDSS worsening in early RRMS Rozanna Meijboom Received Received
  229-P Frequency of Spinal Cord Atrophy in Pediatric Onset Multiple Sclerosis Kimberly ONeill Received Received
  244-P Exploring the Relationship Between Regional Cortical Thinning and Neurofilament Light Chain in Early Relapsing-Remitting MS Sarah Levy Received Received
  256-P Propionate, a Short-Chain Fatty Acid, is associated with Disease Activity in MS Vinicius Schoeps Received Received
  257-P Brain-derived blood extracellular vesicles as potential biomarkers in multiple sclerosis (MS): Pilot results from relapsing MS patients receiving anti-CD20 therapy Shamundeeswari Anandan Received Received
  258-P Prognostic Value of Baseline Serum Neurofilament Light Chain Levels in People With Relapsing Multiple Sclerosis by Prior Treatment Status and DMT Type Anupam Dwesar Received Received
  266-P Real-World Utilization of a Multi-Proteomic, Serum-Based Assay for Assessing Response to Therapy in Persons with Multiple Sclerosis Jonathan Doty Received Received
  291-P Exploratory Biomarker Analyses Support Frexalimab Mechanism of Action in Participants with Relapsing Multiple Sclerosis Shailaja Mahajan-Thakur Received Received
  293-P Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa Franz Felix Konen Received Received
  307-P Preclinical Evidence that Liver-Targeted Antigen Therapies Induce Regulatory T-Cells and Control Immune Responses in Diseased Tissues and Result in Remission of Disease Tom Thornley Received Received
  317-P Remyelination in multiple sclerosis lesions after oral cladribine: a 2-year prospective study Giordani Rodrigues dos Passos Received Received
  318-P European experience of cladribine tablets in elderly multiple sclerosis : Could it be the last treatment ? jerome de Seze Received Received
  321-P Incidence of relapses after meningococcal vaccination in clinical trials and real-world evidence of eculizumab and ravulizumab in AQP4-Ab NMOSD Alexia Perugini Received Received
  324-P Five years of Ublituximab in relapsing multiple sclerosis: additional results from open-label extension of ULTIMATE I and II studies Victoria Findlen Received Received
  329-P Efficacy and tolerability of ublituximab after transitioning from a different disease modifying therapy: Updates from the ENHANCE study Victoria Findlen Received Received
  330-P Effect of autologous hematopoietic stem cell transplantation on fatigue in multiple sclerosis Veronika Kana Received Received
  332-P Phase 2 Trial of SAR443820 (RIPK1 Inhibitor) in Relapsing and Progressive Multiple Sclerosis: K2 Study Design and Baseline Characteristics Deepa Warrier Received Received
  339-P Time to multiple sclerosis reactivation after anti-CD20 treatment discontinuation : a retrospective observational study from 4 large French MS Reference centers in the OFSEP national Database. Hugo VIGIER Received Received
  341-P Earlier high efficacy therapy is associated with less work disability in relapsing multiple sclerosis: a nationwide observational cohort study Anna He Received Received
  353-P Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab Lisa Revie Received Received
  358-P Retrospective analysis of multiple sclerosis patients who initiated oral cladribine more than 4 years ago data from a German cladribine cohort Petra Joestingmeyer Received Received
  364-P Real life effectiveness and tolerability of Cladribine after 3 years of treatment: multicenter study in Galicia (CLADRIGAL) Antonio Pato Received Received
  370-P A Higher Mediterranean Diet Score is Prospectively Associated with Better Mental Health and Quality of Life in a National Multiple Sclerosis Cohort Maggie Yu Received Received
  372-P An Absence of Pelvic Floor Physical Therapy Referrals in MS Patients Experiencing Bladder Dysfunction Valerie Block Received Received
  388-P Multiple sclerosis treatment strategies and disease activity during pregnancy and post-partum: real-world data from the Swiss MS cohort Einsiedler Maximilian Received Received
  392-P Long-Term Ofatumumab Treatment Over 6 Years Did Not Increase the Risk of Serious Infections Saimithra Thammera Received Received
  405-P Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study Sonia Pham Received Received
  412-P Clinical Course and Origin of Critical Demyelinating Lesion-Associated Progressive Motor Impairment in Multiple Sclerosis Nabeela Nathoo Received Received
  500-P A consensus study developing clinical guidelines for neurologist to use when communicating a misdiagnosis of Multiple Sclerosis. Angela Baufeldt Received Received
  505-P The Impact of Complement Inhibition on Lesion Extension and Recovery in Neuromyelitis Optica Jeffrey Bennett Received Received
  513-P Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder: Frequency and type of cancer co-existence, antigen expression and proof of paraneoplastic phenotype. Naga Pradyumna Kothapalli Received Received
  518-P Apheresis in MOGAD: retrospective data of 117 therapeutic interventions from the German Neuromyelitis Optica Study Group (NEMOS) Carolin Schwake Received Received
  532-P Clinical Profile and Treatment Outcome in Chronic Relapsing Inflammatory Optic Neuropathy: a Longitudinal Retrospective Study Madalina Graure Received Received
  563-P Low sun exposure and seasonal effect in the risk of pediatric MS: the PEDIGREE Study Silvy Pilotto Received Received
  567-P Assessing the impact of Immune Checkpoint Inhibitor therapy on disease activity in Multiple Sclerosis patients Saira Afzal Received Received
  573-P Progression independent of relapsing biology in multiple sclerosis Carlos Camara Lemarroy Received Received
  577-P Acute clinical events identified as relapses but with stable MRI in multiple sclerosis Antoine Gavoille Received Received
  580-P Impact of Age at Onset on Neuromyelitis Spectrum Disorder in Latin America: Contrasting Early-Onset and Late-Onset Disease Milena Sales Pitombeira Received Received
  583-P Cross-sectional and prospective associations between a more pro-inflammatory diet and patient-reported health outcomes in people living with multiple sclerosis from the United Kingdom MS Register Jeanette Reece Received Received
  592-P Four years on: Pregnancy and birth outcomes reported in the MSBase Pregnancy, Neonatal outcomes and Womens Health Registry (2020-2024) Vilija Jokubaitis Received Received
  599-P Intraindividual Variability in Gait and Cognitive Reaction Time as a Prodromal Marker of Functional Decline Giuseppina Pilloni Received Received
  602-P Evaluating the impact of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a randomized controlled trial and qualitative analysis Nathan Y. Chu Received Received
  614-P Prevalence and impact of migraine in multiple sclerosis: a cross-sectional observational single-centre study Jelena Skuljec Received Received
  615-P Psychiatric morbidity during the multiple sclerosis prodrome is associated with increased future disability Anibal Chertcoff Received Received
  618-P Cannabis Use Disorder in MS: A Pilot RCT of a Home-Based tDCS Intervention Leigh Charvet Received Received
  619-P A multicenter evaluation of the relationship between brainstem lesions and apnea hypopnea index in patients with multiple sclerosis Elle Levit Received Received
  620-P Lack of changes in symptom severity from COVID-19 infection in Multiple Sclerosis Amber Salter Received Received
  660-P Humoral response to COVID-19 variants in people with Multiple Sclerosis: Impact of Anti-CD20 Therapy Anna He Received Received
  661-P Selected T lymphocytes Specific for Autologous Epstein-Barr Virus Infected Cell Lines Are Enriched in Multiple Sclerosis Cerebrospinal Fluid John Lindsey Received Received
  666-P Mediterranean Diet is Associated with a Proxy for Atrophy in Multiple Sclerosis Ilana Katz Sand Received Received
  667-P Clostridium perfringens epsilon toxin: A rapid element of the gut-brain axis targeting CD4 T cells, central nervous system endothelial cells, oligodendrocytes, and myelin timothy vartanian Received Received
  673-P Abrogating demyelination inhibits synapse loss in an animal model of multiple sclerosis Tara DeSilva Received Received
  677-P MS Perilesional White Matter Abnormalities detected on MRI may largely represent Residual Damage from the Acute Stage of Lesion Formation Colm Elliott Received Received
  678-P Differences in Spatial Distribution of T2-Lesions and Gd Lesions Identify Areas of the Brain where T2-Lesions may Accumulate in the Absence of BBB Breakdown Colm Elliott Received Received
  683-P Greater choroid plexus volume predicts severe disease course after 10 years of clinical onset in multiple sclerosis: a real-life study. Fanny Magne Received Received
  697-P MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Positive Patients and Validation of Current Diagnostic Criteria Jodie Burton Received Received
  701-P Choroid Plexus Volume in Pediatric-Onset Multiple Sclerosis Eleonora Grasso Received Received
  705-P Long-term impact of spinal cord reserve on disability progression in multiple sclerosis Paola Ajdinaj Received Received
  720-P Imaging Tract-Specific Effects of Lesion Load on Diffusion-Derived Markers in Normal-Appearing White Matter Microstructure in People with Multiple Sclerosis Hannah Bernstein Received Received
  723-P Iron rim lesions in newly diagnosed highly active Multiple Sclerosis patients: correlation with clinical and radiological measures. Alessandra Cicia Received Received
  728-P Superior Sensitivity of Detection of Paramagnetic Rim Lesions on Filtered Phase versus Enhanced Magnitude on Vendor-Provided Susceptibility Weighted Imaging Joshua Lee Received Received
  730-P Black Americans with MS have greater atrophy in critical relays of cerebellum, thalamus, and spinal cord than White Americans with MS Nabeela Nathoo Received Received
  732-P Multiple Sclerosis and disability progression in anti-CD20 treated patients: a radiomics approach. Ivan Panzera Received Received
  734-P Enhanced Diffusion Fibre Orientation Distribution for Patients with Multiple Sclerosis Chenyu Wang Received Received
  750-P Micro-RNA Signature in Cerebrospinal Fluid Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis Ivan Pavlovic Received Received
  751-P Real world clinical experience with MOG and AQP4 antibody testing by live vs fixed cell-based assays Yana Said Received Received
  753-P Serum Neurofilament Changes in Progressive MS: Exploring the Impact of Vidofludimus Calcium by Age and Disability Insights from the CALLIPER Study Interim Analysis. Valentina Sciacca Received Received
  768-P From blood to brain: Linking plasma biomarkers to magnetic resonance imaging findings in multiple sclerosis Katrin Wolfova Received Received
  774-P Exploratory Blood-Based Biomarkers for Phase 1b/2 Trials in Multiple Sclerosis: Evaluation of Circulating Brain Derived Extracellular Vesicles Jennifer Linden Received Received
  782-P Neurophysiological and Structural Bases of Fatigue in Multiple Sclerosis alberto benelli Received Received
  785-P Digital Gait Metrics for Disability Level Differentiation Using Spatiotemporal parameters in Multiple Sclerosis Valerie Block Received Received
  787-P Eye Movement Biomarkers Predict Early Cognitive Dysfunction in Multiple Sclerosis Francois Blanchette Received Received
  792-P Common genetic variation and polygenicity associated with dimethyl fumarate-induced lymphopenia in multiple sclerosis Kaarina Kowalec Received Received
  796-P Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator Tyler Molitor Received Received
  798-P Determinants of time delay between recommendation for and start of high-efficacy treatment in Multiple Sclerosis Valentin Krüger Received Received
  806-P Baseline data from OVERLORD-MS Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease ivind Torkildsen Received Received
  809-P Cladribine decreases migration of memory B cells across an in vitro blood brain barrier in multiple sclerosis Rachel K. Ford Received Received
  813-P Progressive multifocal leukoencephalopathy in a patient treated with siponimod for secondary progressive multiple sclerosis UROS ROT Received Received
  814-P Allogeneic virus-specific T-cells in multiple sclerosis patients with progressive multifocal leukoencephalopathy Lea Grote-Levi Received Received
  817-P Lipoic Acid for Treatment of Progressive Multiple Sclerosis (PMS); Results of a Phase 2 Randomized Placebo-Controlled Trial Carin Waslo Received Received
  830-P Exploratory MRI Outcomes and Plasma NfL Levels in Frexalimab-Treated Participants with Relapsing Multiple Sclerosis: Week 48 Results from the Phase 2 Open-Label Extension Anubhav Mehra Received Received
  838-P Sustained efficacy of cladribine tablets in the longer term: A real-world, multicentre study Wallace Brownlee Received Received
  840-P ACAPELLA: Real-World Experience with Ocrelizumab, 7-Year Data Paige Greenawalt Received Received
  842-P Immediate High Efficacy Treatment in Multiple Sclerosis is Associated With Long Term Reduction in Progression Independent of Relapse Activity (PIRA) compared to Low-Moderate efficacy treatment A Swedish MS Registry Study Tim Spelman Received Received
  850-P Real-World Experience of Rituximab in the treatment of CNS Demyelinating disorders from a LMIC region: India. Netravathi M Received Received
  851-P Pharmacovigilance in a real-world data setting a comparative study Elena Flavia Mouresan Received Received
  857-P Effectiveness and Safety of Satralizumab in a Real-world Clinical Setting in Japan: Interleukin-6 Receptor Inhibition in Neuromyelitis Optica Spectrum Disorders: A Six-month Interim Analysis of Multicenter Medical Chart Review Vandana Bhargav Received Received
  858-P Changes in paediatric-onset multiple sclerosis treatment strategy over time: real world data from the Swiss Paediatric Inflammatory Brain Disease Registry Isabella Christen Received Received
  862-P Real world experience with siponimod in Active Secondary Progressive Multiple Sclerosis: Results of the RESYZE study Carmen Barrull Received Received
  867-P Predictors of psychotherapy use in people with multiple sclerosis: Clinical data from an Ontario-based neuropsychiatry clinic David Freedman Received Received
  892-P Engagement patterns of Floodlight MS, a smartphone-based tool for remote monitoring of disability progression William Conte Received Received
  902-P Specific immune response after EBV infection predicts the risk of developing MS Rommer Paulus Received Received
  908-P Evidence for Clostridium perfringens epsilon toxin within active MS lesions: Implications for etiopathogensis Vartanian Timothy Received Received
  913-P Regional Variations in Multiple Sclerosis Epidemiology and Healthcare Access: Insights from the BRANDO Database in Brazil Cintia Ramari Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
06:48
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

 

18-20 September 2024 Copenhagen
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 18/09/2024 TO 18/09/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert